EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Phase 3

Completed

• Conditions: Congestive Heart Failure

• Registration Number: NCT00071331
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).

Detailed Description

Study Design: Multicenter, randomized, double-blind, placebo-controlled

Study Timeline

• Study Start: 2003-09
• Study First Submitted: 2003-10-20
• Study First Submitted QC: 2003-10-20
• Study First Posted: 2003-10-21
• Primary Completion: 2006-07
• Study Completion: 2006-07
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-02
• Last Update Posted: 2012-05-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3600

Inclusion Criteria

• Age greater than or equal to 18 years.
• Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to randomization. Chronic heart failure is defined as requiring treatment for a minimum of 30 days prior to hospitalization.

The subject must have signs of extracellular volume expansion, defined as two or more of the following: a) jugular venous distention; b) pitting edema (>1+); or c) dyspnea.

• NYHA Class III or IV at the time of hospitalization.
• Left Ventricular Ejection Fraction < = 40% within one year.

Exclusion Criteria

• Women who will not adhere to the reproductive precautions as outlined in the Informed Consent form.
• Positive urine pregnancy test.
• Inability to provide written informed consent.
• Cardiac surgery within 60 days of potential study enrollment, excluding percutaneous coronary interventions.
• Planned revascularization procedures, electrophysiologic (EP) device implantation, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study enrollment.
• Subjects who are on cardiac mechanical support.
• History of bi-ventricular pacer placement within the last 60 days.
• Co-morbid condition with an expected survival less than six months.
• Subjects with acute ST segment elevation myocardial infarction at the time of hospitalization.
• History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator.
• History of a cerebrovascular accident within the last 30 days.
• Hemodynamically significant uncorrected primary cardiac valvular disease.
• Hypertrophic cardiomyopathy (obstructive or non-obstructive).
• CHF due to uncorrected thyroid disease, active myocarditis or known amyloid cardiomyopathy.
• Subjects with progressive or episodic neurological disease such as multiple sclerosis or history of multiple strokes.
• History of primary significant liver disease or acute hepatic failure, as defined by the investigator.
• History of poorly controlled diabetes mellitus.
• Morbid obesity, defined as > 159 kg (or 350 lbs) or BMI > 40.
• Supine systolic arterial blood pressure < 90 mmHg.
• Serum creatinine > 3.5 mg/dL or > 309.4 mmol/L.
• Serum potassium > 5.5 mEq/L or > 5.5 mmol/L.
• Hemoglobin < 9 g/dL or < 90 g/L.
• History of hypersensitivity and/or idiosyncratic reaction to benzazepine derivatives (such as benazapril).
• History of drug or medication abuse within the past year, or current alcohol abuse.
• Inability to take oral medications.
• Participation in another clinical drug or device trial within the past 30 days.
• Previous participation in this or any other tolvaptan clinical trial.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (355)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

The Heart Center; 🇺🇸 Huntsville, Alabama, United States

The Heart Group; 🇺🇸 Mobile, Alabama, United States

Phoenix Memorial Hospital; 🇺🇸 Gilbert, Arizona, United States

Arizona Heart Institute; 🇺🇸 Phoenix, Arizona, United States

Saguaro Clinical Research; 🇺🇸 Tucson, Arizona, United States

Central Arkansas Veterans Healthcare Systems; 🇺🇸 Little Rock, Arkansas, United States

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Bakersfield Memorial Hospital; 🇺🇸 Bakersfield, California, United States

Central Cardiology Medical Center; 🇺🇸 Bakersfield, California, United States

Scroll for more (345 remaining)